Table 2.
Clinical characteristics of patients regarding PD-L1 expression
| Characteristics | All, n | PD-L1 < 50%, n | (%) | PD-L1 ≥ 50, n | (%) | p |
|---|---|---|---|---|---|---|
| All patients | 117 | 82 | 70.1 | 35 | 29.9 | |
| Age (years) | 0.236 | |||||
| Median | 61.0 | 60.5 | 64 | |||
| Range | 47–77 | 47–77 | 50–75 | |||
| Gender | 0.117 | |||||
| Female | 38 | 23 | 28 | 15 | 42.9 | |
| Male | 79 | 59 | 72 | 20 | 57.1 | |
| Histology | 0.201 | |||||
| Squamous | 71 | 48 | 58.5 | 23 | 65.7 | |
| Adeno | 39 | 27 | 32.9 | 12 | 34.3 | |
| Other | 7 | 7 | 8.5 | 0 | 0 | |
| Smoking status | 0.702 | |||||
| Current | 67 | 49 | 60.5 | 18 | 52.9 | |
| Former | 44 | 29 | 35.8 | 15 | 44.2 | |
| Never | 4 | 3 | 3.7 | 1 | 2.9 | |
| Stage | 0.0230 | |||||
| IIIA | 30 | 17 | 20.7 | 13 | 37.1 | |
| IIIB | 75 | 59 | 72.0 | 16 | 45.7 | |
| IIIC | 12 | 6 | 7.3 | 6 | 17.1 | |
| ECOG PS | 0.625 | |||||
| 0 | 58 | 41 | 50.0 | 17 | 48.6 | |
| 1 | 57 | 39 | 47.6 | 18 | 51.4 | |
| 2 | 2 | 2 | 2.4 | 0 | 0 | |
| RT dose (Gy) | 0.639 | |||||
| Median | 60 | 60 | ||||
| Range | 54–66 | 54–66 | ||||
| ChT (number of cycles) | 0.666 | |||||
| Median | 3 | 3 | ||||
| Range | 1–5 | 1–5 | ||||
| CRP after ChT/RT | 0.447 | |||||
| ≤ 2 × ULN | 74 | 51 | 62.2 | 23 | 69.7 | |
| > 2 × ULN | 41 | 31 | 37.8 | 10 | 30.3 |
ChT chemotherapy, ECOG PS Eastern Cooperative Oncology Group performance status, n number, RT radiotherapy, CRP C-reactive protein, ULN upper limit of normal